Utilization of 31P-Nuclear Magnetic Resonance Spectroscopy to Monitor Brain Energy Deficit in Huntington Disease
PRO-MH2
Study of the Brain Energy Profile Evolution, Using 31Phosphorus-Nuclear Magnetic Resonance Spectroscopy, at Different Stages of Huntington Disease
2 other identifiers
interventional
50
1 country
1
Brief Summary
The purpose of this project is to study brain energy profile evolution at different stages of the Huntington disease.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable
Started Dec 2012
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
September 20, 2012
CompletedFirst Posted
Study publicly available on registry
October 1, 2012
CompletedStudy Start
First participant enrolled
December 6, 2012
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 1, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
November 1, 2015
CompletedDecember 10, 2025
September 1, 2012
2.9 years
September 20, 2012
December 3, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Ratio of Inorganic Phosphate (Pi) over phosphocreatine (PCr): Pi/PCr
31P-MRS allows quantification of high-energy phosphate metabolites such as phosphocreatine and inorganic phosphate
2 years
Secondary Outcomes (2)
Correlation between primary outcome measure and clinical parameters
2 years
Study of longitudinal changes in Pi/PCr ratio over time.
2 years
Study Arms (2)
Patients
OTHER31-Phosphorus RMN Spectroscopy
Volunteers
OTHER31-Phosphorus RMN Spectroscopy
Interventions
Eligibility Criteria
You may qualify if:
- UHDRS \< 50
- Age \> 18 years
- Ability to undergo MR scanning
- Covered by french social security
You may not qualify if:
- Evidence of psychiatric disorder
- Attendant neurological disorder
- Contraindications to MRI (claustrophobia, metallic or material implants)
- Severe head injury
- Unable to understand the protocol
- Pregnancy
- Failure to give informed consent
- Unwillingness to be informed in case of abnormal MRI
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Brain and Spine Institute (ICM)
Paris, 75013, France
Related Publications (2)
Adanyeguh IM, Monin ML, Rinaldi D, Freeman L, Durr A, Lehericy S, Henry PG, Mochel F. Expanded neurochemical profile in the early stage of Huntington disease using proton magnetic resonance spectroscopy. NMR Biomed. 2018 Mar;31(3):10.1002/nbm.3880. doi: 10.1002/nbm.3880. Epub 2018 Jan 9.
PMID: 29315899RESULTAdanyeguh IM, Rinaldi D, Henry PG, Caillet S, Valabregue R, Durr A, Mochel F. Triheptanoin improves brain energy metabolism in patients with Huntington disease. Neurology. 2015 Feb 3;84(5):490-5. doi: 10.1212/WNL.0000000000001214. Epub 2015 Jan 7.
PMID: 25568297RESULT
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Fanny Mochel, MD, PhD
INSERM UMR S975 Institut du Cerveau et de la Moelle, AP-HP Département de Génétique, Université Pierre et Marie Curie, Paris France
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER GOV
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
September 20, 2012
First Posted
October 1, 2012
Study Start
December 6, 2012
Primary Completion
November 1, 2015
Study Completion
November 1, 2015
Last Updated
December 10, 2025
Record last verified: 2012-09